Mizuho Maintains ResMed (RMD) Outperform Recommendation

Mizuho has maintained an Outperform recommendation for ResMed (NYSE:RMD), with an average one-year price target of $301.14, suggesting a 21.97% upside from its latest closing price of $246.89. This outlook comes despite projected annual revenue decreasing by 8.62% to $4,804MM, alongside a projected non-GAAP EPS of $8.94. Institutional sentiment appears mixed, with an increase in the number of funds reporting positions by 5.29%, yet total shares owned by institutions decreased by 0.94%, and a put/call ratio of 4.26 indicates a bearish options market outlook.

Analysis

Mizuho has reiterated an "Outperform" rating for ResMed (RMD), setting an average one-year price target of $301.14, implying a 21.97% upside from its recent $246.89 closing price. This bullish analyst outlook contrasts with a projected annual revenue decrease of 8.62% to $4,804MM, though a non-GAAP EPS of $8.94 is also forecasted. The divergence between a positive price target and declining revenue projections is a key point of interest.

Institutional sentiment for RMD appears mixed, reflecting a nuanced view among large investors. The number of funds reporting positions increased by 5.29% to 1,713, and average portfolio weight rose by 4.22% to 0.23%. However, total institutional shares owned decreased by 0.94% over the last three months, suggesting some larger holders may have trimmed stakes despite broader interest.

Further complicating sentiment, the put/call ratio of 4.26 indicates a distinctly bearish outlook within the options market. Conversely, several major institutional investors like Vanguard funds and Geode Capital Management increased their shareholdings and portfolio allocations in RMD, with share increases ranging from 1.49% to 2.34% and allocation increases from 4.38% to 7.62%. Bank of New York Mellon reduced its share count by 3.14% but still increased its portfolio allocation by 6.59%.

Key Decisions for Investors

• Investors should reconcile Mizuho's "Outperform" rating and 21.97% price target upside with the projected 8.62% revenue decline, seeking clarity on the drivers of the analyst's optimism despite fundamental headwinds.
• Monitor future institutional ownership trends, particularly the divergence between increasing fund participation and decreasing total shares, to understand conviction levels and potential rebalancing activities.
• Evaluate the bearish signal from the high 4.26 put/call ratio as a potential indicator of short-term downside risk or hedging activity, which could influence tactical positioning.
• Conduct further due diligence on the factors contributing to the projected 8.62% revenue decrease, assessing whether this is a temporary headwind or indicative of a more structural challenge for ResMed.